David James Lennon Sells 9,689 Shares of Aadi Bioscience, Inc. (NASDAQ:AADI) Stock

Aadi Bioscience, Inc. (NASDAQ:AADI) CEO David James Lennon sold 9,689 shares of Aadi Bioscience stock in a transaction that occurred on Thursday, October 3rd. The stock was sold at an average price of $1.94, for a total transaction of $18,796.66. Following the completion of the sale, the chief executive officer now directly owns 22,869 shares of the company’s stock, valued at approximately $44,365.86. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Aadi Bioscience Price Performance

Shares of Aadi Bioscience stock opened at $1.94 on Friday. The company’s fifty day simple moving average is $1.70 and its 200-day simple moving average is $1.77. The stock has a market capitalization of $47.63 million, a PE ratio of -0.76 and a beta of 0.70. Aadi Bioscience, Inc. has a 1-year low of $1.21 and a 1-year high of $5.70.

Aadi Bioscience (NASDAQ:AADI) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.71) by $0.17. The business had revenue of $6.18 million for the quarter, compared to analysts’ expectations of $6.33 million. Aadi Bioscience had a negative net margin of 274.77% and a negative return on equity of 66.67%. During the same quarter last year, the company posted ($0.67) EPS. As a group, research analysts anticipate that Aadi Bioscience, Inc. will post -2.02 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of AADI. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Aadi Bioscience during the 2nd quarter valued at $37,000. Marquette Asset Management LLC purchased a new position in shares of Aadi Bioscience during the 1st quarter valued at $135,000. Finally, Acuitas Investments LLC lifted its stake in shares of Aadi Bioscience by 10.8% during the 2nd quarter. Acuitas Investments LLC now owns 352,483 shares of the company’s stock valued at $515,000 after buying an additional 34,344 shares in the last quarter. Hedge funds and other institutional investors own 52.08% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on AADI shares. HC Wainwright restated a “neutral” rating on shares of Aadi Bioscience in a research note on Wednesday, August 21st. Jefferies Financial Group cut Aadi Bioscience from a “buy” rating to a “hold” rating and dropped their target price for the stock from $11.00 to $1.50 in a research report on Wednesday, August 21st. Piper Sandler Companies lowered shares of Aadi Bioscience from an “overweight” rating to a “neutral” rating and set a $1.75 price target for the company. in a research report on Tuesday, August 27th. TD Cowen downgraded shares of Aadi Bioscience from a “buy” rating to a “hold” rating in a report on Wednesday, August 21st. Finally, Piper Sandler lowered shares of Aadi Bioscience from an “overweight” rating to a “neutral” rating and cut their target price for the company from $5.00 to $1.75 in a research report on Tuesday, August 27th. Five equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $10.25.

About Aadi Bioscience

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.